Deva Holding Share Price

Equities

DEVA

TRADEVAW91E2

Pharmaceuticals

Delayed Borsa Istanbul 14:26:02 14/06/2024 BST 5-day change 1st Jan Change
89.25 TRY -0.78% Intraday chart for Deva Holding +0.85% +18.27%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2022 4.48B 137M 10.81B Sales 2023 11.33B 347M 27.35B Capitalization 15.11B 463M 36.48B
Net income 2022 1.36B 41.67M 3.28B Net income 2023 3.38B 104M 8.17B EV / Sales 2022 3.55 x
Net Debt 2022 2.06B 63.21M 4.98B Net Debt 2023 1.92B 58.96M 4.65B EV / Sales 2023 1.5 x
P/E ratio 2022
10.2 x
P/E ratio 2023
4.46 x
Employees 2,908
Yield 2022
0.22%
Yield 2023
-
Free-Float 17.78%
More Fundamentals * Assessed data
Dynamic Chart
Deva Holding A.S. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tod's rises 17% on L Catterton bids to help owner's delisting plan RE
Deva Holding A.S. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Deva Holding A.S. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Deva Holding A.S. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Deva Holding A.S. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Deva Holding A.S. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Deva Holding A.S. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Deva Holding A.S.(IBSE:DEVA) dropped from S&P Global BMI Index CI
Deva Holding A.S. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Deva Holding A.S. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Deva Holding A.S. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Deva Holding A.S. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Deva Holding A.S. Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Deva Holding A.S. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
More news
1 day-0.67%
1 week+0.85%
Current month-2.24%
1 month+14.19%
3 months+18.03%
6 months+16.80%
Current year+18.27%
More quotes
1 week
86.00
Extreme 86
92.00
1 month
75.75
Extreme 75.75
106.00
Current year
67.05
Extreme 67.05
106.00
1 year
41.40
Extreme 41.4
106.00
3 years
21.50
Extreme 21.5
106.00
5 years
5.19
Extreme 5.19
106.00
10 years
1.88
Extreme 1.88
106.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 13/07/06
Director of Finance/CFO 45 13/03/08
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chief Executive Officer - 13/07/06
Director of Finance/CFO 45 13/03/08
Director/Board Member - 21/05/13
More insiders
Date Price Change Volume
14/06/24 89.25 -0.78% 1 126 735
13/06/24 89.95 +0.95% 770,501
12/06/24 89.1 +1.83% 894,584
11/06/24 87.5 -1.24% 603,475
10/06/24 88.6 0.00% 882,059

Delayed Quote Borsa Istanbul, June 14, 2024 at 02:26 pm

More quotes
Deva Holding AS is a Turkey-based pharmaceutical company that is primarily engaged in the production and marketing of finished pharmaceutical products, pharmaceutical ingredients and veterinary products, as well as animal health products, among others. The Company has four production facilities in Turkey. Its production facilities include the Tokapi, Cerezkoy I, Cerezkoy II and Kartepe production plants. The Company’s product portfolio comprises 73 drugs, which are available on the market in 177 various forms. It offers products, such as Azitro, Alemax, Cefax, Inhibace, Imatis, Hydrea, Kardozin, Kristapen, Magcar, Magnesie Calcinee, Nostil, Oceral, Remidon, Prolixin and Quet, among others. The Company has two subsidiaries, namely Vetaa Veteriner ve Tarim Ilaclari A.S. and Deva Holding NZ Ltd.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW